Source comparison
CJC-1295 No DAC & Ipamorelin Work for Dual-Pathway GH Research: Comparison
CJC-1295 No DAC alone GHRH receptor agonism → cAMP-mediated GH release 150–180% Yes (short half-life) Minimal 100–200 mcg 1–2×/day Amplifies endogenous pulses but cannot access ghrelin pathway. Leaves synergy unrealised Ipamorelin alone Ghrelin receptor agonis
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC alone
- GHRH receptor agonism → cAMP-mediated GH release
- 150–180%
- Yes (short half-life)
- Minimal
- 100–200 mcg 1–2×/day
- Amplifies endogenous pulses but cannot access ghrelin pathway. Leaves synergy unrealised
- Ipamorelin alone
- Ghrelin receptor agonism → IP3-mediated calcium mobilization
- 120–160%
- Yes
- None (highly selective)
- 200–300 mcg 1–2×/day
- Clean GH elevation without off-target effects but limited by single-pathway mechanism
- CJC-1295 + Ipamorelin (dual-pathway)
- Simultaneous GHRH + ghrelin receptor activation → convergent signaling amplification
- 300–350%
- Yes (when dosed ≤2×/day)
- Minimal to none
- 100–200 mcg CJC + 200–300 mcg ipamorelin 1–2×/day
- Synergistic GH release through independent pathways. The mechanistic standard for dual-pathway GH research
- GHRP-6 + CJC-1295
- GHRH + ghrelin agonism (older generation)
- 250–300%
- Moderate (cortisol, prolactin, appetite surge)
- Variable
- Effective GH elevation but off-target activation limits experimental precision
- CJC-1295 DAC (long-acting)
- Sustained GHRH receptor agonism → chronic cAMP elevation
- 200–250% sustained
- No (flattens pulsatility)
- Moderate (chronic GH → negative feedback)
- 500–1000 mcg 1×/week
- Produces sustained supraphysiological GH but eliminates natural pulse architecture. Inappropriate for pulsatility studies